文献速递免疫规划职业卫生

医务人员10年麻疹、腮腺炎和风疹加强疫苗接种规划的影响:一项横断面研究

Impact of 10-year measles, mumps and rubella booster vaccination program among healthcare personnel: a cross-sectional study.
PubMed 文献 · Vaccine · 2025-09-23

该单中心横断面研究于2021年12月至2023年4月纳入732名医务人员及健康体检者,评估单剂MMR加强疫苗接种10年后的血清阳性率;麻疹、腮腺炎、风疹血清阳性率分别为89.8%、91.0%、88.0%,成年期接种MMR加强疫苗与麻疹和腮腺炎血清阳性相关,10年间未发现医务人员麻疹感染或院内传播。

要点

  • 麻疹、腮腺炎、风疹总体血清阳性率分别为89.8%、91.0%、88.0%。
  • 31-40岁组麻疹血清阳性率最低:医务人员80.4%,健康体检者82.4%。
  • 成年期接种MMR加强疫苗与麻疹(aOR 2.77)和腮腺炎(aOR 2.39)血清阳性相关。

核心结论

  • MMR加强疫苗接种规划在维持MMR高血清阳性率方面可行且有效,尤其对免疫可能衰减的风险医务人员。

研究设计与样本

  • 单中心横断面研究,于2021年12月至2023年4月纳入732名参与者,包括528名医务人员和204名健康体检者。
  • 自2013年起,医院为在高风险单位工作及1981年或之后出生(≤41岁)的医务人员提供单剂MMR加强疫苗;符合台湾CDC麻疹免疫操作标准者豁免。
  • 检测MMR特异性IgG抗体并获取详细疫苗接种史。

主要发现

  • 参与者中位年龄43岁,74.6%为女性。
  • 麻疹、腮腺炎、风疹总体血清阳性率分别为89.8%、91.0%、88.0%。
  • 麻疹血清阳性率在31-40岁参与者中最低:医务人员80.4%,健康体检者82.4%。
  • 多变量分析中,年龄与麻疹血清阳性相关(每增加1岁,aOR 1.08;95%CI 1.04-1.12)。
  • 成年期接种MMR加强疫苗与麻疹血清阳性(aOR 2.77;95%CI 1.46-5.24)和腮腺炎血清阳性(aOR 2.39;95%CI 1.23-4.65)相关。

临床怎么用

  • 作者认为MMR加强疫苗接种规划可行且有效,尤其对免疫可能衰减的风险医务人员。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The study aimed to assess the effects of a single-dose measles, mumps, and rubella (MMR) booster vaccination, without prior testing, on MMR immunity and infection among vulnerable healthcare personnel (HCP) 10 years after implementation in a highly vaccinated population. METHODS: We conducted a single-center, cross-sectional study to assess the MMR seroprevalence in HCP and health examinees enrolled from December 2021 through April 2023. Since 2013, the hospital has provided a single-dose MMR booster vaccine to HCP working in high-risk units and those born in or after 1981 (≤41 years of age). HCP who met the Taiwan CDC's operational criteria for measles immunity were exempted. MMR-specific IgG antibodies were measured, and detailed vaccination histories were obtained. RESULTS: A total of 732 participants were enrolled, including 528 HCP and 204 health examinees. The median age was 43 years, and 74.6 % were female. The overall seroprevalence rates of measles, mumps, and rubella were 89.8 %, 91.0 % and 88.0 %, respectively. The measles seroprevalence rate was lowest among participants aged 31-40 years (80.4 % in HCP and 82.4 % in health examinees). In multivariable analysis, age was associated with measles seropositivity (per 1-year increase, aOR, 1.08; 95 % CI 1.04-1.12). Receiving MMR booster vaccination in adulthood was associated with seropositivity for measles (aOR, 2.77; 95 % CI, 1.46-5.24) and mumps (aOR, 2.39; 95 % CI, 1.23-4.65). No cases of measles acquisition or intra-hospital spread were identified among HCP during the past 10 years. CONCLUSIONS: An MMR booster vaccination program is feasible and effective in maintaining high seropositivity rates for MMR, particularly among HCP at risk of waning immunity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hwang LE, Lin KY, Tseng PH, et al. Impact of 10-year measles, mumps and rubella booster vaccination program among healthcare personnel: a cross-sectional study. Vaccine. 2025. PMID: 40992077. doi:10.1016/j.vaccine.2025.127758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。